<DOC>
	<DOCNO>NCT02655393</DOCNO>
	<brief_summary>Part A : The study double-blind , randomize , single ascending dos , study 24 healthy elderly male female volunteer . Each subject randomize two subsequent dos three cohort . Part B : The study double-blind , randomize , multiple ascend dos study 36 healthy elderly male female volunteer . Subjects randomize receive study product placebo 28 day .</brief_summary>
	<brief_title>A Single Multiple Dose Study AMAZ-02 Evaluate Safety Pharmacokinetics Elderly Subjects</brief_title>
	<detailed_description>Part A : Single Ascending Dose study AMAZ-02 3 cohort ( cohort n=8 subject , total n=24 subject ) . Cohorts undergo two period single dose intervention separate 3 week washout . Adverse event , clinical biochemistry safety assessment plasma urine collect pharmacokinetic measurement parent metabolite level circulation . Part B : Multiple Ascending Dose study 3 cohort ( cohort n=12 subject , total n=36 subject ) . 28 day administration AMAZ-02 safety , PK PD assessment .</detailed_description>
	<criteria>1 . Healthy male female elderly subject , age 61 85 year inclusive ; 2 . Nonsmoker subject smoker 5 cigarette day ; 3 . Body Mass Index ( BMI ) 18 32 kg/m2 inclusive ; 4 . Certified healthy comprehensive clinical assessment ( detailed medical history complete physical examination ) ; 5 . Normal Blood Pressure ( BP ) Heart Rate ( HR ) screen visit 10 minute supine position : 95 mmHg ≤ Systolic Blood Pressure ( SBP ) ≤ 160 mmHg , 50 mmHg ≤ Diastolic Blood Pressure ( DBP ) ≤ 95 mmHg , 50 bpm &lt; HR &lt; 80 bpm , Or consider NCs investigator ; 6 . Normal ECG record 12lead ECG screen visit : 120 &lt; PR &lt; 220 m , QRS &lt; 120 m , QTcf &lt; 430 m male &lt; 450 ms female , No sign trouble sinusal automatism , Or consider NCS investigator ; 7 . Laboratory parameter within normal range laboratory ( haematological , blood chemistry test , urinalysis ) . Individual value normal range accept judge clinically non relevant Investigator ; 8 . Normal dietary habit ; 9 . Demonstrate sedentary behaviour define activity category 1 assess International Physical Activity Questionnaire ( IPAQ ) . Activity level &lt; 600 MET ( metabolic equivalent unit minute per week limit light intensity activity . 10 . Accept refrain consume certain food supplement least two week inclusion . 11 . Comprehension nature purpose study ability communicate person telephone manner allow protocol procedure carry safety reliably opinion investigative site staff 12 . Ability take 8 capsule study medication 13 . Signing write informed consent prior selection ; 14 . Covered Health Insurance System / compliance recommendation National Law force relate biomedical research . 1 . Any history presence cardiovascular , pulmonary , gastrointestinal , hepatic , renal , metabolic , hematological , neurologic , psychiatric , systemic infectious disease ; 2 . Frequent headache / migraine , recurrent nausea / vomiting ; 3 . Symptomatic hypotension whatever decrease blood pressure asymptomatic postural hypotension define decrease SBP DBP equal great 20 mmHg within two minute change supine stand position ; 4 . Blood donation ( include frame clinical trial ) within 2 month administration ; 5 . General anaesthesia within 3 month administration ; 6 . Presence history drug hypersensitivity , allergic disease diagnose treated physician ; 7 . Lactose intolerance , milk protein soy allergy . 8 . Inability abstain intensive muscular effort ; 9 . No possibility contact case emergency ; 10 . Use prohibit medication detailed concomitant medication section 11 . History presence drug alcohol abuse ( alcohol consumption &gt; 40 gram / day ) ; 12 . Excessive consumption beverage xanthine base ( &gt; 4 cup glass / day ) ; 13 . Positive Hepatitis B surface ( HBs ) antigen anti Hepatitis C Virus ( HCV ) antibody , positive result Human Immunodeficiency Virus ( HIV ) 1 2 test ; 14 . Positive result screen drug abuse ; 15 . Subject , judgment Investigator , likely noncompliant uncooperative study , unable cooperate language problem , poor mental development ; 16 . Exclusion period previous study ; 17 . Administrative legal supervision ; 18 . Subjects participate previous clinical trial last 3 month receive compensation beyond certain approved predefined limit</criteria>
	<gender>All</gender>
	<minimum_age>61 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>